Publication Name	World Journal of Gastroenterology
Manuscript ID	15253
Country	Italy

Received	2014-11-18 08:36
Peer-Review Started	2014-11-18 15:30
To Make the First Decision	2014-12-26 13:30
Return for Revision	2015-01-05 16:23
Revised	2015-01-08 16:27
Second Decision	2015-02-10 21:22
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-02-11 15:35
Articles in Press	2015-02-11 16:18
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-03-04 09:24
Publish the Manuscript Online	2015-03-16 18:04

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Targeted therapy in first line treatment of RAS wild type colorectal cancer
Manuscript Source	Invited Manuscript
All Author List	Vincenzo Formica and Mario Roselli
Funding Agency and Grant Number
Corresponding Author	Vincenzo Formica, MD, PhD, Medical Oncology Unit, Department of Internal Medicine, “Tor Vergata” University Hospital, Viale Oxford 81, 00133 Rome, Italy. vincenzo.formica@uniroma2.it
Key Words	Colorectal cancer; Bevacizumab; Cetuximab; Panitumumab; RAS
Core Tip	Three new randomized head-to-head trials have explored the use of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor targeted agents in chemotherapy-naive metastatic colorectal cancer patients not carrying activating mutations of RAS proteins.
Publish Date	2015-03-16 18:04
Citation	Formica V, Roselli M. Targeted therapy in first line treatment of RAS wild type colorectal cancer. World J Gastroenterol 2015; 21(10): 2871-2874
URL	http://www.wjgnet.com/1007-9327/full/v21/i10/2871.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i10.2871

Full Article (PDF)	WJG-21-2871.pdf
Full Article (Word)	WJG-21-2871.doc
Manuscript File	15253-Review.doc
Answering Reviewers	15253-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	15253-Conflict-of-interest statement.pdf
Copyright License Agreement	15253-Copyright assignment.pdf
Peer-review Report	15253-Peer-review(s).pdf
Scientific Misconduct Check	15253-Scientific misconduct check.pdf
Scientific Editor Work List	15253-Scientific editor work list.pdf